Document Detail


Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
MedLine Citation:
PMID:  15363049     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dialysis patients show a high prevalence of cardiovascular complications among which left ventricular hypertrophy is one of the most frequent and is independently predictive of mortality. A recent study indicates that partial regression of left ventricular hypertrophy improves mortality and reduces cardiovascular events in end-stage renal disease (ESRD) patients, suggesting the importance of targeting therapeutic strategies to reduce cardiac hypertrophy and improve the outcome in these patients. The pathogenesis of left ventricular hypertrophy in ESRD patients is multifactorial and includes hypertension, activation of the renin-angiotensin system, increased sympathetic activity, chronic volume overload, chronic anaemia and hyperparathyroidism. In this paper, we review the available experimental and clinical evidence showing the important contribution of the renin-angiotensin system as well as its interaction with the sympathetic nervous system in the pathogenesis of left ventricular hypertrophy in ESRD patients. Furthermore, we summarize the results of currently available clinical studies that examined the effects of angiotensin-converting enzyme inhibition or angiotensin receptor antagonism on left ventricular hypertrophy in ESRD patients, and review evidences that support the use of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists in the ESRD population.
Authors:
Angela Yee-Moon Wang; Philip Kam-Tao Li; Siu-Fai Lui; John E Sanderson
Related Documents :
20071839 - Left ventricular hypertrophy in hypertension: correlation between electrocardiography a...
8154429 - Echocardiographic findings in 104 professional cyclists with follow-up study.
8441179 - Coronary dilator reserve and morphological changes after relief of pressure-overload in...
2150039 - Left ventricular hypertrophy sensitizes the myocardium to the development of ischaemia.
11737969 - Ultrasonic tissue characterization: review of an approach to assess hypertrophic myocar...
17704109 - Cardiovascular remodelling and extracellular fluid excess in early stages of chronic ki...
24642559 - Metabolic characteristics of human hearts preserved for 12 hours by static storage, ant...
10320249 - Influence of diabetes mellitus on early and late outcome after coronary artery bypass g...
7549189 - Geographical variations in the presentation of ruptured aneurysms of sinuses of valsalv...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nephrology (Carlton, Vic.)     Volume:  9     ISSN:  1320-5358     ISO Abbreviation:  Nephrology (Carlton)     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-09-14     Completed Date:  2004-12-16     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9615568     Medline TA:  Nephrology (Carlton)     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  190-7     Citation Subset:  IM    
Affiliation:
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin New Territories, Hong Kong. awang@cuhk.edu.hk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Animals
Blood Pressure
Humans
Hypertrophy, Left Ventricular / drug therapy*,  etiology,  physiopathology
Kidney Failure, Chronic / complications*
Prognosis
Renin-Angiotensin System / physiology
Sympathetic Nervous System / physiopathology
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bilateral infundibulopelvic stenosis without renal insufficiency: is surgery necessary?
Next Document:  Pentoxifylline: a potential therapy for chronic kidney disease.